They should treat device trust as an end-to-end governance problem. That means secure provisioning, signed update paths, vulnerability remediation processes, and explicit ownership through decommissioning. If those elements are not connected, the device may look compliant at launch but fail under audit or in the field.
Why This Matters for Security Teams
For MedTech, CRA lifecycle compliance is not just a product engineering concern. It is a trust and evidence problem that spans manufacturing, secure provisioning, software updates, vulnerability handling, and end-of-life decommissioning. The EU Cyber Resilience Act pushes teams to prove that security is maintained across the full product lifecycle, not only at launch.
That matters because medical devices often operate for years, in mixed hospital networks, with long-lived service accounts, embedded secrets, and update paths that are difficult to change once fielded. NHIMG’s Ultimate Guide to NHIs frames this as a lifecycle governance issue: if identity, secrets, and ownership are not maintained continuously, the device can drift out of compliance even when the initial release was sound.
Security teams often underestimate how audit evidence fails in practice. A device can have signed firmware, but still fail CRA expectations if the update authority is not traceable, the remediation workflow is manual, or decommissioning leaves active credentials behind. In practice, many teams discover lifecycle gaps only after a field incident or audit finding, rather than through intentional control testing.
How It Works in Practice
Prepare for CRA by treating each device as a governed asset with a complete identity and support lifecycle. That starts before shipment: secure provisioning must establish unique device identity, controlled secrets, and signed configuration baselines. It continues in the field with authenticated update channels, vulnerability intake, patch prioritisation, and clear ownership for who can approve remediation. The NIST Cybersecurity Framework 2.0 is useful here because it forces teams to connect governance, protect, detect, respond, and recover rather than treating compliance as a single control.
For MedTech teams, the practical control model should include:
- Unique device identity and provisioning records tied to manufacturing and release batches.
- Signed update mechanisms with verified provenance and rollback protection.
- Documented vulnerability intake, triage, and patch decision criteria.
- Ownership mapping across engineering, security, quality, and regulatory functions.
- Decommissioning steps that revoke credentials, disable remote access, and archive evidence.
NHIMG’s NHI Lifecycle Management Guide is especially relevant because the same lifecycle failures that affect NHIs also affect devices with embedded service identities. Current guidance suggests using lifecycle registers, secret rotation evidence, and release approvals as audit artifacts, but there is no universal standard for how much evidence is sufficient across every product class. The 2025 State of NHIs and Secrets in Cybersecurity found that 50% of organisations are onboarding new vaults without proper security approval, which is a useful warning for MedTech teams expanding device or service credential management without formal review. These controls tend to break down when legacy devices cannot support revocation or signed updates because remediation then depends on compensating controls instead of native enforcement.
Common Variations and Edge Cases
Tighter lifecycle control often increases engineering and quality overhead, requiring organisations to balance assurance against release speed and support cost. That tradeoff is real in MedTech, especially for legacy devices, shared hospital infrastructure, and products with long certification cycles.
Best practice is evolving for situations where devices cannot be patched quickly or where field service access is mediated through third parties. In those cases, teams should document compensating controls such as segmented access, shorter-lived service credentials, monitored maintenance windows, and explicit sunset plans. The OWASP Non-Human Identity Top 10 remains relevant because CRA readiness often depends on avoiding secret sprawl, overused identities, and weak ownership, even when the underlying issue is a device rather than a cloud service.
Another edge case is decommissioning. Devices retired from clinical use still need identity shutdown, secret revocation, and evidence retention. If that step is skipped, the asset may remain reachable through remote support channels or stale credentials long after it leaves service. NHIMG’s Top 10 NHI Issues is a practical reminder that lifecycle failure, not just initial misconfiguration, is what usually creates audit exposure. Teams should plan for legacy constraints early, because CRA compliance becomes hardest when a device is safe enough to keep in service but too constrained to modernise cleanly.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
OWASP Non-Human Identity Top 10 address the attack surface, NIST CSF 2.0 set the technical controls, and EU Cyber Resilience Act define the regulatory obligations.
| Framework | Control / Reference | Relevance |
|---|---|---|
| EU Cyber Resilience Act | Directly governs product lifecycle cybersecurity duties for MedTech devices. | |
| NIST CSF 2.0 | GV.OC-01 | Lifecycle compliance depends on clear product ownership and operating context. |
| OWASP Non-Human Identity Top 10 | NHI-03 | Embedded device identities fail when credentials are static or poorly rotated. |
Map each device to CRA lifecycle evidence for secure development, updates, vulnerability handling, and decommissioning.
Related resources from NHI Mgmt Group
Deepen Your Knowledge
Reviewed and updated by the NHIMG editorial team on June 25, 2026.
NHI Mgmt Group — the #1 independent authority on Non-Human Identity, IAM, and Agentic AI security. nhimg.org
